SOUTH SAN FRANCISCO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc., a leader in innovative biologics, announced today that Julia P. Gregory, president and chief executive officer, and Jeffrey Finer, M.D., Ph.D., vice president of discovery, will present at the 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York, New York. Their presentation will take place on Monday, February 14, 2011, at 8:00 a.m., Eastern Standard Time. Ms. Gregory and Dr. Finer will present an overview of FivePrime and discuss the company's clinical and preclinical development programs and collaborations.
Five Prime Therapeutics, Inc. is a clinical-stage, privately held, biotechnology company discovering and developing innovative protein and antibody therapeutics. FivePrime is currently testing FP-1039, a first-in-class biologic, in a Phase 1 study for patients with solid tumors and will soon begin a Phase 2 trial in mutant endometrial cancer. Using its novel high-tech discovery platform, FivePrime is building a strong pipeline of oncology, immunology and metabolic disease drug candidates. Its proprietary platform mines FivePrime's library of all the secreted and extracellular human proteins to screen for medically relevant new therapeutic proteins and antibody targets. FivePrime has active collaborations with Pfizer, Inc. in the fields of oncology and diabetes and GlaxoSmithKline for skeletal muscle disorders. For more information, visit .
The Five Prime Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8029
CONTACT: Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco, CA 94080 Debbie Tobin, 415-365-5721 Debbie.Tobin@fiveprime.com